← All trials
NCT01730534
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 25, 2013
- Primary completion
- Apr 29, 2019
- Completion date
- Apr 29, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 17276
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- AstraZenecaStudy director
- TIMI Study Group, Boston, MAStudy chair
- TIMI Study Group, Boston, MAOverall official - principal investigator
- The TIMI Study GroupCollaborator
- Bristol-Myers SquibbCollaborator
- Hebrew UniversityOverall official - principal investigator
- Hebrew UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.